Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cedazuridine/decitabine (Primary) ; Nivolumab (Primary)
Indications Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Rectal cancer; Vulvovaginal cancer
Focus Adverse reactions

05 Dec 2024 Status changed from recruiting to active, no longer recruiting.
26 Jun 2024 Planned primary completion date changed from 26 Jul 2024 to 26 Jul 2025.
25 May 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com